Christopher Ntoumenopoulos

Tryptamine Therapeutics Limited | Non-Executive Director

Mr Ntoumenopoulos has over 20 years of experience in financial markets in both capital raising and corporate strategy. He serves as the Managing Director of Twenty1 Corporate, an Australian-based corporate advisory firm that provides funding and corporate support for innovative companies and technologies.

Companies and Roles

Company	Title	Tenure	Since
TYP Tryptamine Therapeutics Limited	Non-Executive Director	7mth	May 2024
MEB Medibio Limited	Non-Executive Director	1yrs, 9mth	Feb 2023
ILA Island Pharmaceuticals Limited	Non-Executive Director	2mth	Sep 2024
NSB NeuroScientific Biopharmaceuticals Ltd	Non-Executive Director Non-Executive Chairman	1yrs	Nov 2023
TRI TrivarX Ltd	Non-Executive Director	1yrs, 9mth	Feb 2023

Holdings

Company	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
ILA Island Pharmaceuticals Limited	04/12/24	0	1,689,136	1,689,136	N/A
TRI TrivarX Ltd	04/12/24	0	6,971,912	14,029,167	N/A
TYP Tryptamine Therapeutics Limited	02/12/24	N/A	6,250,000	37,546,580	N/A
NSB NeuroScientific Biopharmaceuticals Ltd	17/11/23	0	N/A	N/A	N/A
MEB Medibio Limited	22/06/23	0	N/A	N/A	N/A

Transactions

Company	Date	Type	Amount	Price	Value	Notes
ILA Island Pharmaceuticals Limited	04/12/24	Issued	1,689,136	$0.070	$118,239	Issue of securities
ILA Island Pharmaceuticals Limited	04/12/24	Issued	1,689,136	$0.170	$287,153	Issue of options
TRI TrivarX Ltd	04/12/24	Issued	4,000,000	$0.010	$40,800	Issue of options
TRI TrivarX Ltd	04/12/24	Issued	909,090	$0.022	$20,000	Director remuneration
TYP Tryptamine Therapeutics Limited	02/12/24	Issued	15,750,000	$0.048	$756,000	Issue of options

Any feedback about this profile? Contact Us

My Watchlists

Fetching your watchlist...